Email Alert RSS
Volume 14 Issue 2
Mar.  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
CUI Ting, LI Jinzhou, LEI Xia, LI Ji'ang, FENG Jie, HUANG Xiaojun. Current Status and Controversies in the Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 359-365. DOI: 10.12290/xhyxzz.2022-0643
Citation: CUI Ting, LI Jinzhou, LEI Xia, LI Ji'ang, FENG Jie, HUANG Xiaojun. Current Status and Controversies in the Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 359-365. DOI: 10.12290/xhyxzz.2022-0643
shu

Current Status and Controversies in the Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms

  • 1.

    The Second Clinical Medical College of Lanzhou University, Lanzhou 730000, China

  • 2.

    Department of Gastroenterology, The Second Hospital of Lanzhou University, Lanzhou 730000, China

Funds: 

Science and Technology Foundation Program for Young Scientists of Gansu Province 21JR1RA155

Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital 2020QN-12

More Information
  • Corresponding author:

    HUANG Xiaojun, E-mail: huangxj@lzu.edu.cn

  • Received Date: November 10, 2022
  • Accepted Date: December 12, 2022
  • Available Online: December 12, 2022
  • Issue Publish Date: March 29, 2023
    Graphical Abstract
    • Abstract
  • With the increasing morbidity of gastric neuroendocrine neoplasms (G-NENs), the understanding of clinicians about G-NENs is also deepening. However, there are still many controversies regarding the diagnosis and treatment of G-NENs. Therefore, this article reviews the current status of diagnosis and treatment of G-NENs through a literature review, and discusses the existing controversies, with the aim of providing reference for clinicians in standardized diagnosis and treatment.
    • FullText(HTML)
    • References (60)
  • [1]
    刘雪梅, 庹必光. 胃肠神经内分泌肿瘤的内镜诊断与治疗[J]. 中华胃肠外科杂志, 2021, 24: 854-860. https://cdmd.cnki.com.cn/Article/CDMD-10366-1021716199.htm
    [2]
    Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors[J]. CA Cancer J Clin, 2018, 68: 471-487. DOI: 10.3322/caac.21493
    [3]
    Exarchou K, Stephens NA, Moore AR, et al. New Developments in Gastric Neuroendocrine Neoplasms[J]. Curr Oncol Rep, 2022, 24: 77-88. DOI: 10.1007/s11912-021-01175-y
    [4]
    Roberto GA, Rodrigues CMB, Peixoto RD, et al. Gastric neuroendocrine tumor: A practical literature review[J]. World J Gastrointest Oncol, 2020, 12: 850-856. DOI: 10.4251/wjgo.v12.i8.850
    [5]
    中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组. 胃肠胰神经内分泌肿瘤诊治专家共识(2020·广州)[J]. 中华消化杂志, 2021, 41: 76-87. DOI: 10.3760/cma.j.cn311367-20210104-00007
    [6]
    谭煌英. 胃神经内分泌肿瘤临床分型的共识和争议[J]. 中华胃肠外科杂志, 2017, 20: 977-981.
    [7]
    Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms[J]. Neuroendocrinology, 2012, 95: 74-87. DOI: 10.1159/000335595
    [8]
    Delle Fave G, O'Toole D, Sundin A, et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms[J]. Neuroendocrinology, 2016, 103: 119-124. DOI: 10.1159/000443168
    [9]
    徐建明, 梁后杰, 秦叔逵, 等. 中国胃肠胰神经内分泌肿瘤专家共识(2016年版)[J]. 临床肿瘤学杂志, 2016, 21: 927-946. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201610013.htm
    [10]
    李洁, 张盼盼. 胃神经内分泌肿瘤的诊治现状[J]. 中国医师进修杂志, 2017, 40: 656-660. https://www.cnki.com.cn/Article/CJFDTOTAL-XHYX202302020.htm
    [11]
    Domori K, Nishikura K, Ajioka Y, et al. Mucin phenotype expression of gastric neuroendocrine neoplasms: analysis of histopathology and carcinogenesis[J]. Gastric Cancer, 2014, 17: 263-272. DOI: 10.1007/s10120-013-0281-7
    [12]
    Pak LM, Yang T, Wang J. Further Classification for Node-Positive Gastric Neuroendocrine Neoplasms[J]. J Gastrointest Surg, 2019, 23: 720-729. DOI: 10.1007/s11605-018-3845-3
    [13]
    Gluckman CR, Metz DC. Gastric Neuroendocrine Tumors (Carcinoids)[J]. Curr Gastroenterol Rep, 2019, 21: 13. DOI: 10.1007/s11894-019-0684-7
    [14]
    Sansone A, Lauretta R, Vottari S, et al. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropan-creatic Tumors[J]. Cancers (Basel), 2019, 11: 1113. DOI: 10.3390/cancers11081113
    [15]
    Filosso PL, Kidd M, Roffinella M, et al. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression[J]. Eur J Cardiothorac Surg, 2018, 53: 631-639. DOI: 10.1093/ejcts/ezx386
    [16]
    Modlin IM, Kidd M, Bodei L, et al. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract[J]. Am J Gastroenterol, 2015, 110: 1223-1232. DOI: 10.1038/ajg.2015.160
    [17]
    Malczewska A, Procner A, Walter A, et al. The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK[J]. BMC Gastroenterol, 2020, 20: 235. DOI: 10.1186/s12876-020-01348-2
    [18]
    van Treijen MJC, Korse CM, van Leeuwaarde RS, et al. Blood Transcript Profiling for the Detection of Neuroendo-crine Tumors: Results of a Large Independent Validation Study[J]. Front Endocrinol (Lausanne), 2018, 9: 740. DOI: 10.3389/fendo.2018.00740
    [19]
    Zilli A, Arcidiacono PG, Conte D, et al. Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows[J]. Dig Liver Dis, 2018, 50: 6-14.
    [20]
    Kos-Kudła B, Blicharz-Dorniak J, Strzelczyk J, et al. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours)[J]. Endokrynol Pol, 2017, 68: 79-110. DOI: 10.5603/EP.2017.0015
    [21]
    Yu R, Wachsman A. Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, and Pitfalls[J]. Endocrinol Metab Clin North Am, 2017, 46: 795-814. DOI: 10.1016/j.ecl.2017.04.008
    [22]
    Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging[J]. J Clin Oncol, 2005, 23: 70-78. DOI: 10.1200/JCO.2005.01.013
    [23]
    Barat M, Soyer P, Al Sharhan F, et al. Magnetic Resonance Imaging May Be Able to Identify the Origin of Neuroendocrine Tumor Liver Metastases[J]. Neuroendocrinology, 2021, 111: 1099-1110. DOI: 10.1159/000513015
    [24]
    Inaba Y, Hijioka S, Iwama I, et al. Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms[J]. Asia Ocean J Nucl Med Biol, 2022, 10: 1-13.
    [25]
    Yu J, Li N, Li J, et al. The Correlation Between[(68)Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs[J]. Mol Imaging Biol, 2019, 21: 984-990. DOI: 10.1007/s11307-019-01328-3
    [26]
    Carideo L, Prosperi D, Panzuto F, et al. Role of Combined[(68)Ga]Ga-DOTA-SST Analogues and[(18)F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review[J]. J Clin Med, 2019, 8: 1032. DOI: 10.3390/jcm8071032
    [27]
    Delpassand ES, Ranganathan D, Wagh N, et al. (64)Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial[J]. J Nucl Med, 2020, 61: 890-896. DOI: 10.2967/jnumed.119.236091
    [28]
    Johnbeck CB, Knigge U, Loft A, et al. Head-to-Head Comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors[J]. J Nucl Med, 2017, 58: 451-457. DOI: 10.2967/jnumed.116.180430
    [29]
    Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76: 182-188. DOI: 10.1111/his.13975
    [30]
    Zheng X, Guo K, Wasan HS, et al. A population-based study: how to identify high-risk T1 gastric cancer patients?[J]. Am J Cancer Res, 2021, 11: 1463-1479.
    [31]
    Shah MH, Goldner WS, Benson AB, et al. Neuroendocr-ine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2021, 19: 839-868. DOI: 10.6004/jnccn.2021.0032
    [32]
    Daskalakis K, Tsoli M, Karapanagioti A, et al. Recurr-ence and metastatic potential in Type 1 gastric neuroendocr-ine neoplasms[J]. Clin Endocrinol (Oxf), 2019, 91: 534-543. DOI: 10.1111/cen.14055
    [33]
    王玮, 周志伟. 胃神经内分泌肿瘤的外科治疗[J]. 中华胃肠外科杂志, 2021, 24: 849-853. DOI: 10.3760/cma.j.cn.441530-20210716-00284
    [34]
    Fukui Y, Kato Y, Okazaki Y, et al. A 3mm Gastric Neuroendocrine Tumor That Metastasized to a Lymph Node[J]. Gan To Kagaku Ryoho, 2018, 45: 1839-1841.
    [35]
    Hirasawa T, Yamamoto N, Sano T. Is endoscopic resection appropriate for type 3 gastric neuroendocrine tumors? Retrospective multicenter study[J]. Dig Endosc, 2021, 33: 408-417. DOI: 10.1111/den.13778
    [36]
    Chen J, Wang A, Ji K, et al. Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study[J]. BMC Cancer, 2020, 20: 777. DOI: 10.1186/s12885-020-07281-7
    [37]
    Stueven AK, Kayser A, Wetz C, et al. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future[J]. Int J Mol Sci, 2019, 20: 3049. DOI: 10.3390/ijms20123049
    [38]
    Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group[J]. J Clin Oncol, 2009, 27: 4656-4663. DOI: 10.1200/JCO.2009.22.8510
    [39]
    Vinik AI, Wolin EM, Liyanage N, et al. Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (Elect): A Randomized, Double-Blind, Placebo-Controlled Trial[J]. Endocr Pract, 2016, 22: 1068-1080. DOI: 10.4158/EP151172.OR
    [40]
    Gut P. Oncological management of advanced neuroendocrine tumours (Review)[J]. Mol Clin Oncol, 2020, 13: 8.
    [41]
    Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence[J]. Expert Opin Pharmacother, 2018, 19: 909-928. DOI: 10.1080/14656566.2018.1476492
    [42]
    Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2016, 387: 968-977. DOI: 10.1016/S0140-6736(15)00817-X
    [43]
    Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364: 514-523. DOI: 10.1056/NEJMoa1009290
    [44]
    Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase Ⅱ trial[J]. J Clin Oncol, 2010, 28: 69-76. DOI: 10.1200/JCO.2009.24.2669
    [45]
    Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2011, 378: 2005-2012. DOI: 10.1016/S0140-6736(11)61742-X
    [46]
    Hasskarl J. Everolimus[J]. Recent Results Cancer Res, 2018, 211: 101-123.
    [47]
    谈思源, 陈平. 胃肠胰神经内分泌瘤的药物治疗进展[J]. 中华临床医师杂志(电子版), 2016, 10: 2158-2162. DOI: 10.3877/cma.j.issn.1674-0785.2016.14.026
    [48]
    Pobłocki J, Jasińska A, Syrenicz A, et al. The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition[J]. Nutrients, 2020, 12: 1437. DOI: 10.3390/nu12051437
    [49]
    Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (AvastinⓇ) in cancer treatment: A review of 15 years of clinical experience and future outlook[J]. Cancer Treat Rev, 2020, 86: 102017. DOI: 10.1016/j.ctrv.2020.102017
    [50]
    Boyce M, Moore AR, Sagatun L, et al. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis[J]. Br J Clin Pharmacol, 2017, 83: 466-475. DOI: 10.1111/bcp.13146
    [51]
    Moore AR, Boyce M, Steele IA, et al. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis[J]. PLoS One, 2013, 8: e76462. DOI: 10.1371/journal.pone.0076462
    [52]
    Lania A, Ferraù F, Rubino M, et al. Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches[J]. Front Endocrinol (Lausanne), 2021, 12: 651438.
    [53]
    Yamamoto M, Ozawa S, Koyanagi K, et al. Effectiveness of neoadjuvant chemotherapy with etoposide and cisplatin followed by surgery for esophageal neuroendocrine carcinoma: a case report[J]. J Thorac Dis, 2018, 10: E450-E455.
    [54]
    Ogawa H, Tanaka Y, Kitamura Y, et al. Efficacy of perioperative chemotherapy for pulmonary high-grade neuroendocrine carcinomas: a propensity score matching analysis[J]. J Thorac Dis, 2019, 11: 1145-1154.
    [55]
    Tang H, Wang H, Xi S, et al. Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review[J]. Onco Targets Ther, 2018, 11: 2557-2563.
    [56]
    Borga C, Businello G, Murgioni S, et al. Treatment personalization in gastrointestinal neuroendocrine tumors[J]. Curr Treat Options Oncol, 2021, 22: 29.
    [57]
    Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135.
    [58]
    Paganelli G, Sansovini M, Nicolini S, et al. (177)Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase Ⅱ prospective study[J]. Eur J Nucl Med Mol Imaging, 2021, 48: 152-160.
    [59]
    Yordanova A, Wicharz MM, Mayer K, et al. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy[J]. Clin Cancer Res, 2018, 24: 4672-4679.
    [60]
    Minczeles NS, Hofland J, de Herder WW, et al. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy[J]. Curr Oncol Rep, 2021, 23: 46.
    • Related Articles

  • Related Articles

    [1]CUI Hanshu, LIU Bin. Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 13-18. DOI: 10.12290/xhyxzz.2024-0802
    [2]LIANG Yan. Interpretation on the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines for the Management of Patients with Chronic Coronary Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 312-319. DOI: 10.12290/xhyxzz.2024-0043
    [3]YU Shiying. Controversies About Palliative Care[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 37-41. DOI: 10.12290/xhyxzz.2023-0537
    [4]LIANG Yun, WU Wenming, NIE Yongzhan, CHEN Jie. Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 94-100. DOI: 10.12290/xhyxzz.2022-0607
    [5]Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, Gitelman Syndrome Consensus Working Group. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 902-912. DOI: 10.12290/xhyxzz.2021-0555
    [6]WU Wenming, CHEN Jie, BAI Chunmei, YIHEBALI Chi, DU Yiqi, FENG Shiting, HUO Li, JIANG Yuxin, LI Jingnan, LOU Wenhui, LUO Jie, SHAO Chenghao, SHEN Lin, WANG Feng, WANG Liwei, WANG Ou, WANG Yu, WU Huanwen, XING Xiaoping, XU Jianming, XUE Huadan, XUE Ling, YANG Yang, YU Xianjun, YUAN Chunhui, ZHAO Hong, ZHU Xiongzeng, ZHAO Yupei, Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association. The Chinese Guidelines for the Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms (2020)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 460-480. DOI: 10.12290/xhyxzz.2021-0481
    [7]An-li TONG, Han-zhong LI. Consensus and Controversy on the Treatment of Multiple Endocrine Neoplasia[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 365-369. DOI: 10.3969/j.issn.1674-9081.2020.04.002
    [8]Ye-ye CHEN, Hong-sheng LIU, Shan-qing LI. Diagnosis and Treatment of Pulmonary Large-cell Neuroendocrine Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(4): 393-397. DOI: 10.3969/j.issn.1674-9081.2019.04.016
    [9]Yan KANG. Treatments of Sepsis and Septic Shock: Advancements in Controversy[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(5): 421-425. DOI: 10.3969/j.issn.1674-9081.2018.05.009
    [10]Ming-sheng MA, Xü-de ZHANG, Min WEI, Shi-min ZHAO, Zheng-qing QIU. Efficacy of Low Dose Corticosteroid Therapy in Duchenne Muscular Dystrophy[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(4): 384-388. DOI: 10.3969/j.issn.1674-9081.2014.04.006

  • Cited by

    Periodical cited type(4)

    1. 付槟梵，裴俊文. 孙太振主任医师采用益气扶正法辨治肺癌经验探讨. 中医研究. 2024(07): 8-12 .
    2. 梁艳，姜溪，武永存，楚丽，段颖欣，王力军. 派安普利单抗联合化疗治疗转移性或局部晚期鳞状非小细胞肺癌的近期疗效和毒副反应. 肿瘤药学. 2024(05): 595-601 .
    3. 田王琪，张蔚桐，汪一凡，郭惠，王育伟，唐于平. 中药多糖通过调控肠道菌群干预肺癌的文献研究. 陕西中医药大学学报. 2023(02): 27-35 .
    4. 白小航，常振东，穆艳艳. 安罗替尼联合多西他赛治疗TP/PDL1靶向失败NSCLC老年患者的疗效分析. 国际医药卫生导报. 2023(24): 3551-3556 .

    Other cited types(8)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1204) PDF downloads (84) Cited by(12)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close